Form 4: Cytek Biosciences CEO Wenbin Jiang Acquires Stock Options and Restricted Stock Units
SEC Form 4 Filing
Wenbin Jiang, CEO of Cytek Biosciences, reports the acquisition of stock options and restricted stock units.
Summary
- On March 6, 2024, Wenbin Jiang, the President and CEO of Cytek Biosciences, acquired stock options for 526,315 shares and 353,606 restricted stock units (RSUs).
- The stock options have an exercise price of $7.07 per share and expire on March 6, 2034, vesting over four years starting April 6, 2024.
- The RSUs represent a contingent right to receive one share of Cytek Biosciences common stock each, vesting over four years with varying amounts vesting on May 18, August 18, November 18, and March 10 of subsequent years.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive as it reflects standard executive compensation practices, aligning management interests with shareholders. There are no immediate negative implications.
Positives
- The acquisition of stock options and RSUs by the CEO aligns his interests with those of the shareholders.
- The vesting schedules of the options and RSUs incentivize long-term performance and commitment from the CEO.
Industry Context
Stock options and restricted stock units are common forms of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation. These grants are designed to incentivize long-term growth and innovation.
Comparison to Industry Standards
- Executive compensation packages including stock options and RSUs are standard practice among publicly traded biotech companies such as Bio-Rad Laboratories and Agilent Technologies.
- The vesting schedules described are typical for executive equity grants, designed to retain key personnel and incentivize long-term performance.
Stakeholder Impact
- Shareholders may view the equity grants positively as they incentivize the CEO to drive long-term value.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 03/06/2024 | Date of transaction for stock options and restricted stock units acquisition. |
| 04/06/2024 | Start date for vesting of stock options (1/48 of total shares). |
| 05/18/2024 | Start date for vesting of restricted stock units (2/48 of total shares). |
| 08/18/2024 | Vesting date for restricted stock units (3/48 of total shares). |
| 11/18/2024 | Vesting date for restricted stock units (3/48 of total shares). |
| 03/10/2025 | Vesting date for restricted stock units (4/48 of total shares). |
| 03/06/2034 | Expiration date of the stock options. |
| 03/08/2024 | Date of signature for the SEC Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.